Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.14363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Kyoung Hwa Ha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Practice Patterns, Physicians'. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer-Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
This study evaluates shifts in oral glucose‐lowering drug prescription patterns and the adoption of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) in South Korea.
Methods
A cross‐sectional and retrospective cohort analysis of the Korean National Health Insurance database (2015–2021) assessed the prescription patterns of oral glucose‐lowering drugs by therapy level, SGLT2i prescriptions by cardiovascular‐renal disease (CVRD) status, and the mean duration for SGLT2i therapy initiation and intensification.
Results
From 2015 to 2021, the number of individuals prescribed oral glucose‐lowering drugs across all regimen levels increased. However, the proportion of individuals receiving monotherapy or dual combination therapy decreased by 9.2 percentage points, whereas the proportion prescribed triple or more combination therapy increased. SGLT2i prescriptions increased from 2.5% in 2015 to 13.9% in 2021, marking an 11.4 percentage point growth. This trend was consistent among individuals with and without CVRD, with the most significant increase observed in individuals with heart failure—from 2.2% in 2015 to 16.6%. The mean time to SGLT2i initiation post‐diagnosis was shortened from 249 days in 2015 to 158 days in 2019.
Conclusions
The adoption of SGLT2i therapy was on the rise, especially among individuals with heart failure, accompanied by a notable decrease in time to treatment initiation. Despite these positive trends, the overall use of SGLT2i among individuals with CVRD remained limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
- Medical Affairs, Boehringer-Ingelheim Korea, Seoul, Korea.
ORCID-Profile: Dae Jung Kim
Förderung
- Boehringer-Ingelheim
Zitieren
APA
Ha, K. H., Shin, S., Na, E., & Kim, D. J. (2025). Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14363
Vancouver
Ha KH, Shin S, Na E, Kim DJ. Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14363
BibTeX
@article{Ha2025,
author = {Ha, Kyoung Hwa and Shin, Soyoung and Na, EunJi and Kim, Dae Jung},
title = {Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.14363}
}
EUVIMED